Pliant Therapeutics Inc (PLRX) - News Archive

In the constantly shifting landscape of pharmaceutical research, Pliant Therapeutics, Inc., based in South San Francisco, has recently made significant strides, only to find themselves pausing for reassessment. The comp...

Pliant Therapeutics Provides Corporate Update and Q1 2025 Financial Results Amid Competitive Landscape Challenges Pliant Therapeutics Inc. has released its corporate update alongside the financial results for the first...

In a strategic move aimed at fortifying its corporate governance and protecting shareholder interests, Pliant Therapeutics, Inc. (Nasdaq: PLRX) has recently adopted a limited duration stockholder rights agreement, also...

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) In a decisive strategic move to bolster its leadership team, Pliant Therapeutics, Inc. (Nasdaq: PLRX) has announced the grant of stock...

Pliant Therapeutics Bolsters Leadership with Strategic Stock Option Grant Amidst Clinical Progress with BexotegrastIn a significant step to enhance its leadership team, Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced...

Pliant Therapeutics Showcases Promising Bexotegrast Data at ERS International Congress 2024 Amidst Financial Challenges By South San Francisco, Calif. September 10, 2024 Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-...

Positive Long-Term Data from INTEGRIS-PSC Phase 2a Trial Demonstrates Tolerability and Efficacy of Bexotegrast at 320 mg Pliant Therapeutics recently reported favorable long-term results from its INTEGRIS-PSC Phase 2a t...

SOUTH SAN FRANCISCO, Calif. - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biopharmaceutical company, has made a significant move in bolstering its leadership team with the appointment of Dr. Chohee Yun as...

Pliant Therapeutics, a renowned late-stage biotechnology company specializing in the development of innovative treatments for fibrotic diseases, made substantial advancements in its Bexotegrast Program during the Europe...

Pliant Therapeutics Presents Success of Bexotegrast Program in Treating Fibrotic DiseasesSOUTH SAN FRANCISCO, Calif., May 21, 2024 - Pliant Therapeutics, a leading clinical-stage biotechnology company specializing in th...

IPF is a chronic, progressive form of lung disease characterized by fibrosis, or scarring, of the lung tissues. The development of excessive collagen, a key component of scar tissues, contributes to the progression of I...

CSIMarket.com is excited to provide an update on the recent advancements made by Pliant Therapeutics in the development of bexotegrast, a potential ground-breaking treatment for Idiopathic Pulmonary Fibrosis (IPF). Plia...

Pliant Therapeutics Faces Revenue Decrease in Q2 2023, but Remains Competitive in Fibrotic Disease MarketSOUTH SAN FRANCISCO, Calif., April 02, 2024 - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a renowned clinical-stage...

Pliant Therapeutics: Speeding Up Bexotegrast Development for Idiopathic Pulmonary Fibrosis TreatmentIn recent news, Pliant Therapeutics, a clinical-stage biopharmaceutical company specializing in fibrotic diseases, has...

Pliant Therapeutics, a leading player in the domain of pharmaceutical industry, recently announced promising safety and exploratory efficacy results from the INTEGRIS-PSC Phase 2a trial of their investigational drug, Be...